220
Publications
30.9K
Citations
73
H-Index
2000
Active since
Richard R. Furman is an author at Cornell University specializing in medicine, immunology, and pathology.
Top concepts
MedicineImmunologyOncologyPathologyImmunotherapyCancer ResearchHematologyPharmacotherapyHealthCancer Therapy
Publications per year
2000–2024
220
220
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.5K citations · Full text
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.2K citations · Full text
Rows per page
1–5 of 220